Literature DB >> 8610645

Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial.

E Maranzano1, P Latini, S Beneventi, E Perruci, B M Panizza, C Aristei, M Lupattelli, M Tonato.   

Abstract

A phase II trial was planned to investigate the feasibility of radiotherapy (RT) without steroids in 20 consecutive patients with metastatic spinal cord compression (MSCC), no neurologic deficits, or only radiculopathy, and no massive invasion of the spine at magnetic resonance imaging (MRI) or computed tomography (CT). Aiming at an early diagnosis, MRI or CT was prescribed for all cancer patients with back pain and osteolysis, even when there were no signs of neurologic spinal compression. All patients were given 30 Gy in 10 fractions over 2 weeks with no steroids. Back pain and motor capacity were the parameters adopted to verify response to RT. Sixteen of 20 patients (80%) were able to walk without support, and 14 (70%) had no radiculopathy. Seventeen of 20 cases (85%) achieved relief from back pain. Regarding motor function, all patients (100%) responded to RT because the 16 patients able to walk without support at diagnosis did not deteriorate and the other 4, who needed support, became ambulatory without motor impairment. Median survival time was 14 months. Eight of 20 (40%) treated patients are still alive (14 to 36 months after end of RT), fully ambulatory, and free from relapse in the treated spine. Acute side effects were documented in only 2 patients (10%) and were managed without steroids. The results of this study suggest that RT without steroids is a feasible regimen for MSCC patients with good motor function. Elimination of steroids from the standard treatment for MSCC avoids cortisone side effects above all in those patients with diabetes, hypertension, peptic ulcer, and other steroid-sensitive medical problems.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610645     DOI: 10.1097/00000421-199604000-00018

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  15 in total

Review 1.  Malignant spinal cord compression.

Authors:  Madhuri Yalamanchili; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2003-12

Review 2.  Spinal cord compression in cancer patients: review of diagnosis and treatment.

Authors:  Marta Penas-Prado; Monica E Loghin
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

Review 3.  Regional pain syndromes in cancer patients.

Authors:  H A Zekry; E Bruera
Journal:  Curr Rev Pain       Date:  2000

Review 4.  The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jim N Rose; Juanita M Crook
Journal:  Ther Adv Urol       Date:  2015-06

Review 5.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

6.  Radiation therapy of metastatic spinal cord compression. Multidisciplinary team diagnosis and treatment.

Authors:  F Kovner; S Spigel; I Rider; I Otremsky; I Ron; E Shohat; J M Rabey; J Avram; O Merimsky; N Wigler; S Chaitchik; M Inbar
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

Review 7.  Tumors of the osseous spine.

Authors:  Narayan Sundaresan; Stephano Boriani; Allen Rothman; Robert Holtzman
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 8.  CNS complications of breast cancer: current and emerging treatment options.

Authors:  Evert C A Kaal; Charles J Vecht
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  Radiotherapeutic approaches to metastatic disease.

Authors:  Edward Chow; Jackson Wu; Andrew Loblaw; Carlos A Perez
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

10.  Epidural Spinal Cord Compression.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Treat Options Neurol       Date:  2004-07       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.